<\/span><\/strong><\/h4>\n<\/span><\/strong><\/h4>\nProf. Dr. Lucian Miron<\/span><\/strong>
Institutul Regional de Oncologie Ia\u015fi<\/span><\/strong>
Universitatea de Medicin\u0103\u00a0\u015fi Farmacie “Grigore T. Popa” Ia\u015fi<\/span><\/strong><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.14″][et_pb_column type=”4_4″ _builder_version=”3.19.14″][et_pb_text _builder_version=”3.19.14″]<\/p>\n
Terapiile sistemice actuale \u00een melanomul malign cutanat<\/span>
Autor: Lucian Miron<\/span><\/span><\/p>\nPrognosticul pacien\u021bilor cu melanom cutanat metastatic este \u00een general nefavorabil. P\u00e2n\u0103 de cur\u00e2nd, melanomul malign metastatic a fost considerata istoric o boala dificila de tratat, cu o rata de supravi\u0163tuire de 10 ani mai redus\u0103 de 10%. Chimiotrapia citotoxic\u0103 cu dacarbazina a fost considerta timp de peste de trei decenii tratamentul standard al formelor de melanommalign metastatic.
Recent, noile clase de medicamente (de exemplu, inhibitorii de checkpoint \u0219i terapii moleculare \u0163intite au ameliorat semnificativ prognosticul pacien\u0163ilor cu melanom maligni. Recunoa\u0219terea BRAF ca o oncogen\u0103-driver tumoral\u0103 important\u0103 \u00een melanom a condus la dezvoltarea de terapii \u0163intite precum dabrafenib \u015fi vemurafenib cu o \u00eembun\u0103t\u0103\u021bire semnificativ\u0103 a ratei de r\u0103spuns, durata controlului bolii \u0219i supravie\u021buirea global\u0103 pentru pacien\u021bii cu melanom metastatic pozitiv cu muta\u021bie BRAF. Terapiile moleculare \u0163intite anti BRAF (dabrafenib, vemurafenib) \u015fi anti MEK (trametinib) sunt eficace \u015fi trebuie utilizate numai la pacien\u0163ii cu muta\u0163ia BRAF V600. Asocierea dintre inhibitorii BRAF \u015fi MEK determin\u0103 ameliorarea rezultate mai bune fa\u0163\u0103 de monoterapia cu inhibitori BRAF.
\u00cen acela\u0219i timp, imunoterapia a evoluat, conduc\u00e2nd la dezvoltarea inhibitorilor \u201echeckpoint\u201d. Primul inhibitor imun checkpoint aprobat \u00een 2011 a fost ipilimumab, un anticorp IgG1 monoclonal complet umanizat, care inhib\u0103 CTLA-4. PD-1, proteina de moarte celular\u0103 programat\u0103 1, este un regulator negativ al activit\u0103\u021bii celulelor T \u0219i este exprimat\u0103 prin celule T cu expunere excesiv\u0103 la antigene. Ligandul s\u0103u, PD-L1, este exprimat frecvent \u00een celulele canceroase \u0219i \u00een limfocitele infiltratoare ale tumorii (TIL). Alt ligand, PD-L2, este exprimat \u00een principal pe celule care prezint\u0103 antigen (APC). Al\u0163i inhibitori, anticorpi anti-PD-1 – nivolumab \u0219i pembrolizumab. Au fost testate multiple vacinuri antitumorale pentru tratarea melanomului avansat. Vaccinurile vizeaz\u0103 ob\u021binerea r\u0103spunsului imun la antigene exprimate de celulele tumorale de melanom, cum ar fi antigenele asociate tumorii (TAA) sau antigenii deriva\u021bi din muta\u021bii (neoantigeni). Administrarea de ipilimumab, nivolumab, pembrolizumab, combina\u021bia dintre ipilimumab \u0219i nivolumab este considerat\u0103 actual un standard terapeutic de tratament \u00een linia I-a indiferent de status\u2013ul BRAF.
Utilizarea inhibitorilor checkpoint determin\u0103 r\u0103spunsuri durabile la mul\u021bi pacien\u021bi cu melanom metastatic, iar tratamentele actuale pot \u00eembun\u0103t\u0103\u021bi supravie\u021buirea pentru mul\u021bi pacien\u021bi cu melanom metastatic. \u00a0<\/p>\n
Sistemic treatments in advanced malignant melanoma<\/span>
Author: Lucian Miron<\/span><\/p>\n The prognosis of patients with metastatic cutaneous melanoma, is generally poor. Until recently, metastatic melanoma had historically been a challenging disease to treat, with a 10-year survival rate of less than 10%. Dacarbazine was the benchmark systemic therapy for this disease for more than 3 decades. after its initial approval in 1975.
Recently, new classes of drugs (e.g. immune checkpoint inhibitors and small-molecule targeted drugs) have significantly improved patient prognosis, which has drastically changed the landscape of melanoma therapeutic management. The recognition of BRAF as an important tumour oncogene in melanoma has led to the development of new targeted therapies.
BRAF and MEK targeted therapy are effective and shoul be use only for patients with BRAF V600 mutated melanoma. Combination BRAF (vemurafenib, dabrafenib) and MEK (trametinib) inhibition results in improved outcomes compared to single-agent BRAF inhibition. All patients with advanced cutaneous melanoma should have their tumor evaluated for the presence of an activating BRAF mutation.
The importance of the immune system in cancer, leading to the development of checkpoint inhibitors. The development of checkpoint inhibitors as a tolerable and effective therapy for metastatic melanoma, which has demonstrated improved response rates, duration of control and overall survival for patients of patients with metastatic melanoma as these therapies are being trialled in other malignancies.
The first checkpoint inhibitors approved by the FDA in 2011 was ipilimumab, a fully human, monoclonal IgG1 antibody that inhibits CTLA-4. Approval of the two anti-PD-1 antibodies\u2014nivolumab and pembrolizumab\u2014followed. PD-1, programmed cell death protein 1, is a negative regulator of T cell activity and is expressed by T cells with excessive exposure to antigens. The other ligand, PD-L2, is expressed mainly by antigen-presenting cells (APCs). Both ligands are members of B7 protein family.
Multiple intratumoral and vaccine approaches have been tested for treating advanced melanoma. The vaccines aim to elicit immune response against antigens expressed by melanoma tumor cells, such as tumor-associated antigens (TAAs) or mutation-derived antigens (neoantigens). Administration of ipilimumab, nivolumab, pembrolizumab, the combination of ipilimumab and nivolumab, and talimogene laherparepvec (T-VEC; for patients with accessible lesions).
Immune checkpoint blockade can achieve durable responses in many patients with metastatic melanoma, and current treatments can improve survival for many metastatic melanoma patients as well as provide hope for a cure for some of them. While meaningful progress is being made, much more work still needs to be accomplished for patients with metastatic melanoma.<\/p>\n
Scurt CV<\/span><\/p>\nAbsolvent al Facult\u0103\u0163ii de Medicin\u0103 \u015fi Farmacie \u201dGrigore T. Popa\u201d Ia\u015fi, este medic primar de Oncologie Medical\u0103, \u015feful Clinicii de Oncologie Medical\u0103, Institutul Regional de Oncologie Ia\u015fi (I.R.O.) , profesor la Disciplina de Oncologie-Radioterapie, U.M.F. \u201dGrigore T. Popa\u201d Ia\u015fi.
Specializat la Institutul Oncologic \u201dAl. Trestioreanu\u201d Bucure\u015fti \u015fi, ulterior cu stagii de preg\u0103tire \u00een Fran\u0163a, Centrul \u201dLeon Berard\u201d Lyon Fran\u0163a, Perugia, Italia \u015fi alte centre. \u015ei-a sus\u0163inut teza de doctorat \u00een domeniul chimioterapiei citotoxice \u00een cancerele bronho-pulmonare non\u2013microcelulare, autor a numeroase articole \u015fi mai multe c\u0103r\u0163i de oncologie dintre care trei tratate de oncologie general\u0103 \u015fi special\u0103. Este specializat \u00een tratamentele sistemice actuale ale cancerelor: mamare, bronho-pulmonare, colo-rectale, genitale feminine, masculin, sarcoame \u015fi altele. Pred\u0103 cursuri la studen\u0163ii la medicin\u0103 U.M.F. \u201dGrigore T. Popa\u201d Ia\u015fi \u015fi este responsabil de preg\u0103tirea medicilor reziden\u0163i \u00een specialitatea de Oncologie Medical\u0103 la I.R.O. Ia\u015fi. Este investigator principal \u00een numeroase studii clinice interna\u0163ionale privind cancerele: mamare, bronho-pulmonare, heatocarcinom, colo-rectale, \u015fi cercetare a mai multe medica\u0163ii oncologice simptomatice. Participant la numeroase manifest\u0103rii oncologice regionale, na\u0163ionale \u015fi interna\u0163ionale este organizatorul \u201d\u015ecolii de Var\u0103\u201d I.R.O. (edi\u0163iile 2014, 2015, 2016, 2017 \u015fi 2018) \u015fi pre\u015fedintele manifest\u0103rii na\u0163ionale \u201dConferin\u0163ele Institutului Regional de Oncologie Ia\u015fi\u201d (CONFER) edi\u0163iile 2012-2018, membru a mai multe societ\u0103\u0163i de cancer na\u0163ionale \u015fi interna\u0163ionale precum: ESMO, ASCO, IASCL \u015fi altele.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical”][et_pb_row custom_padding=”61px|0px|69px|0px|false|false” _builder_version=”3.18.9″][et_pb_column type=”3_5″ _builder_version=”3.18.9″][et_pb_text _builder_version=”3.19.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2019<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”3.19.4″ title_font=”||||||||”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ border_radii=”on||||” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ border_radii=”on||||” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ border_radii=”on||||” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.18.9″][et_pb_text _builder_version=”3.19.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2019<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”3.19.4″ text_font=”||||||||”]![\"\"](\"https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/eventer_logo_150px.png\")
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
\nTel.: 0332.40.88.00-05<\/span>
\nE-mail: inscrieri@pdi.ro\/2019<\/a>
\n<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"Absolvent al Facultatii de Medicina si Farmacie \u201e Grigore.T.Popa\u201d Ia\u015fi, este medic primar de Oncologie Medical\u0103, \u015feful Clinicii de Oncologie Medical\u0103, Institutul Regional de Oncologie Ia\u015fi (IRO) , profesor la Disciplina de Oncologie-Radioterapie, UMF \u201e Grigore T. Popa\u201d Ia\u015fi. Specializat la Institutul Oncologic \u201eAl Trestioreanu\u201d Bucure\u015fti \u015fi, ulterior cu stagii de preg\u0103tire \u00een Fran\u0163a, Centrul […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"class_list":["post-871","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/comments?post=871"}],"version-history":[{"count":7,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/871\/revisions"}],"predecessor-version":[{"id":4265,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/871\/revisions\/4265"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/media?parent=871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Prof. Dr. Lucian Miron<\/span><\/strong>
Institutul Regional de Oncologie Ia\u015fi<\/span><\/strong>
Universitatea de Medicin\u0103\u00a0\u015fi Farmacie “Grigore T. Popa” Ia\u015fi<\/span><\/strong><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.14″][et_pb_column type=”4_4″ _builder_version=”3.19.14″][et_pb_text _builder_version=”3.19.14″]<\/p>\n
Terapiile sistemice actuale \u00een melanomul malign cutanat<\/span>
Autor: Lucian Miron<\/span><\/span><\/p>\nPrognosticul pacien\u021bilor cu melanom cutanat metastatic este \u00een general nefavorabil. P\u00e2n\u0103 de cur\u00e2nd, melanomul malign metastatic a fost considerata istoric o boala dificila de tratat, cu o rata de supravi\u0163tuire de 10 ani mai redus\u0103 de 10%. Chimiotrapia citotoxic\u0103 cu dacarbazina a fost considerta timp de peste de trei decenii tratamentul standard al formelor de melanommalign metastatic.
Recent, noile clase de medicamente (de exemplu, inhibitorii de checkpoint \u0219i terapii moleculare \u0163intite au ameliorat semnificativ prognosticul pacien\u0163ilor cu melanom maligni. Recunoa\u0219terea BRAF ca o oncogen\u0103-driver tumoral\u0103 important\u0103 \u00een melanom a condus la dezvoltarea de terapii \u0163intite precum dabrafenib \u015fi vemurafenib cu o \u00eembun\u0103t\u0103\u021bire semnificativ\u0103 a ratei de r\u0103spuns, durata controlului bolii \u0219i supravie\u021buirea global\u0103 pentru pacien\u021bii cu melanom metastatic pozitiv cu muta\u021bie BRAF. Terapiile moleculare \u0163intite anti BRAF (dabrafenib, vemurafenib) \u015fi anti MEK (trametinib) sunt eficace \u015fi trebuie utilizate numai la pacien\u0163ii cu muta\u0163ia BRAF V600. Asocierea dintre inhibitorii BRAF \u015fi MEK determin\u0103 ameliorarea rezultate mai bune fa\u0163\u0103 de monoterapia cu inhibitori BRAF.
\u00cen acela\u0219i timp, imunoterapia a evoluat, conduc\u00e2nd la dezvoltarea inhibitorilor \u201echeckpoint\u201d. Primul inhibitor imun checkpoint aprobat \u00een 2011 a fost ipilimumab, un anticorp IgG1 monoclonal complet umanizat, care inhib\u0103 CTLA-4. PD-1, proteina de moarte celular\u0103 programat\u0103 1, este un regulator negativ al activit\u0103\u021bii celulelor T \u0219i este exprimat\u0103 prin celule T cu expunere excesiv\u0103 la antigene. Ligandul s\u0103u, PD-L1, este exprimat frecvent \u00een celulele canceroase \u0219i \u00een limfocitele infiltratoare ale tumorii (TIL). Alt ligand, PD-L2, este exprimat \u00een principal pe celule care prezint\u0103 antigen (APC). Al\u0163i inhibitori, anticorpi anti-PD-1 – nivolumab \u0219i pembrolizumab. Au fost testate multiple vacinuri antitumorale pentru tratarea melanomului avansat. Vaccinurile vizeaz\u0103 ob\u021binerea r\u0103spunsului imun la antigene exprimate de celulele tumorale de melanom, cum ar fi antigenele asociate tumorii (TAA) sau antigenii deriva\u021bi din muta\u021bii (neoantigeni). Administrarea de ipilimumab, nivolumab, pembrolizumab, combina\u021bia dintre ipilimumab \u0219i nivolumab este considerat\u0103 actual un standard terapeutic de tratament \u00een linia I-a indiferent de status\u2013ul BRAF.
Utilizarea inhibitorilor checkpoint determin\u0103 r\u0103spunsuri durabile la mul\u021bi pacien\u021bi cu melanom metastatic, iar tratamentele actuale pot \u00eembun\u0103t\u0103\u021bi supravie\u021buirea pentru mul\u021bi pacien\u021bi cu melanom metastatic. \u00a0<\/p>\n
Sistemic treatments in advanced malignant melanoma<\/span>
Author: Lucian Miron<\/span><\/p>\n The prognosis of patients with metastatic cutaneous melanoma, is generally poor. Until recently, metastatic melanoma had historically been a challenging disease to treat, with a 10-year survival rate of less than 10%. Dacarbazine was the benchmark systemic therapy for this disease for more than 3 decades. after its initial approval in 1975.
Recently, new classes of drugs (e.g. immune checkpoint inhibitors and small-molecule targeted drugs) have significantly improved patient prognosis, which has drastically changed the landscape of melanoma therapeutic management. The recognition of BRAF as an important tumour oncogene in melanoma has led to the development of new targeted therapies.
BRAF and MEK targeted therapy are effective and shoul be use only for patients with BRAF V600 mutated melanoma. Combination BRAF (vemurafenib, dabrafenib) and MEK (trametinib) inhibition results in improved outcomes compared to single-agent BRAF inhibition. All patients with advanced cutaneous melanoma should have their tumor evaluated for the presence of an activating BRAF mutation.
The importance of the immune system in cancer, leading to the development of checkpoint inhibitors. The development of checkpoint inhibitors as a tolerable and effective therapy for metastatic melanoma, which has demonstrated improved response rates, duration of control and overall survival for patients of patients with metastatic melanoma as these therapies are being trialled in other malignancies.
The first checkpoint inhibitors approved by the FDA in 2011 was ipilimumab, a fully human, monoclonal IgG1 antibody that inhibits CTLA-4. Approval of the two anti-PD-1 antibodies\u2014nivolumab and pembrolizumab\u2014followed. PD-1, programmed cell death protein 1, is a negative regulator of T cell activity and is expressed by T cells with excessive exposure to antigens. The other ligand, PD-L2, is expressed mainly by antigen-presenting cells (APCs). Both ligands are members of B7 protein family.
Multiple intratumoral and vaccine approaches have been tested for treating advanced melanoma. The vaccines aim to elicit immune response against antigens expressed by melanoma tumor cells, such as tumor-associated antigens (TAAs) or mutation-derived antigens (neoantigens). Administration of ipilimumab, nivolumab, pembrolizumab, the combination of ipilimumab and nivolumab, and talimogene laherparepvec (T-VEC; for patients with accessible lesions).
Immune checkpoint blockade can achieve durable responses in many patients with metastatic melanoma, and current treatments can improve survival for many metastatic melanoma patients as well as provide hope for a cure for some of them. While meaningful progress is being made, much more work still needs to be accomplished for patients with metastatic melanoma.<\/p>\n
Scurt CV<\/span><\/p>\nAbsolvent al Facult\u0103\u0163ii de Medicin\u0103 \u015fi Farmacie \u201dGrigore T. Popa\u201d Ia\u015fi, este medic primar de Oncologie Medical\u0103, \u015feful Clinicii de Oncologie Medical\u0103, Institutul Regional de Oncologie Ia\u015fi (I.R.O.) , profesor la Disciplina de Oncologie-Radioterapie, U.M.F. \u201dGrigore T. Popa\u201d Ia\u015fi.
Specializat la Institutul Oncologic \u201dAl. Trestioreanu\u201d Bucure\u015fti \u015fi, ulterior cu stagii de preg\u0103tire \u00een Fran\u0163a, Centrul \u201dLeon Berard\u201d Lyon Fran\u0163a, Perugia, Italia \u015fi alte centre. \u015ei-a sus\u0163inut teza de doctorat \u00een domeniul chimioterapiei citotoxice \u00een cancerele bronho-pulmonare non\u2013microcelulare, autor a numeroase articole \u015fi mai multe c\u0103r\u0163i de oncologie dintre care trei tratate de oncologie general\u0103 \u015fi special\u0103. Este specializat \u00een tratamentele sistemice actuale ale cancerelor: mamare, bronho-pulmonare, colo-rectale, genitale feminine, masculin, sarcoame \u015fi altele. Pred\u0103 cursuri la studen\u0163ii la medicin\u0103 U.M.F. \u201dGrigore T. Popa\u201d Ia\u015fi \u015fi este responsabil de preg\u0103tirea medicilor reziden\u0163i \u00een specialitatea de Oncologie Medical\u0103 la I.R.O. Ia\u015fi. Este investigator principal \u00een numeroase studii clinice interna\u0163ionale privind cancerele: mamare, bronho-pulmonare, heatocarcinom, colo-rectale, \u015fi cercetare a mai multe medica\u0163ii oncologice simptomatice. Participant la numeroase manifest\u0103rii oncologice regionale, na\u0163ionale \u015fi interna\u0163ionale este organizatorul \u201d\u015ecolii de Var\u0103\u201d I.R.O. (edi\u0163iile 2014, 2015, 2016, 2017 \u015fi 2018) \u015fi pre\u015fedintele manifest\u0103rii na\u0163ionale \u201dConferin\u0163ele Institutului Regional de Oncologie Ia\u015fi\u201d (CONFER) edi\u0163iile 2012-2018, membru a mai multe societ\u0103\u0163i de cancer na\u0163ionale \u015fi interna\u0163ionale precum: ESMO, ASCO, IASCL \u015fi altele.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical”][et_pb_row custom_padding=”61px|0px|69px|0px|false|false” _builder_version=”3.18.9″][et_pb_column type=”3_5″ _builder_version=”3.18.9″][et_pb_text _builder_version=”3.19.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2019<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”3.19.4″ title_font=”||||||||”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ border_radii=”on||||” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ border_radii=”on||||” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ border_radii=”on||||” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.18.9″][et_pb_text _builder_version=”3.19.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2019<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”3.19.4″ text_font=”||||||||”]<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
\nTel.: 0332.40.88.00-05<\/span>
\nE-mail: inscrieri@pdi.ro\/2019<\/a>
\n<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"Absolvent al Facultatii de Medicina si Farmacie \u201e Grigore.T.Popa\u201d Ia\u015fi, este medic primar de Oncologie Medical\u0103, \u015feful Clinicii de Oncologie Medical\u0103, Institutul Regional de Oncologie Ia\u015fi (IRO) , profesor la Disciplina de Oncologie-Radioterapie, UMF \u201e Grigore T. Popa\u201d Ia\u015fi. Specializat la Institutul Oncologic \u201eAl Trestioreanu\u201d Bucure\u015fti \u015fi, ulterior cu stagii de preg\u0103tire \u00een Fran\u0163a, Centrul […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"class_list":["post-871","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/comments?post=871"}],"version-history":[{"count":7,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/871\/revisions"}],"predecessor-version":[{"id":4265,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/871\/revisions\/4265"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/media?parent=871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Autor: Lucian Miron<\/span><\/span><\/p>\n
Prognosticul pacien\u021bilor cu melanom cutanat metastatic este \u00een general nefavorabil. P\u00e2n\u0103 de cur\u00e2nd, melanomul malign metastatic a fost considerata istoric o boala dificila de tratat, cu o rata de supravi\u0163tuire de 10 ani mai redus\u0103 de 10%. Chimiotrapia citotoxic\u0103 cu dacarbazina a fost considerta timp de peste de trei decenii tratamentul standard al formelor de melanommalign metastatic.
Recent, noile clase de medicamente (de exemplu, inhibitorii de checkpoint \u0219i terapii moleculare \u0163intite au ameliorat semnificativ prognosticul pacien\u0163ilor cu melanom maligni. Recunoa\u0219terea BRAF ca o oncogen\u0103-driver tumoral\u0103 important\u0103 \u00een melanom a condus la dezvoltarea de terapii \u0163intite precum dabrafenib \u015fi vemurafenib cu o \u00eembun\u0103t\u0103\u021bire semnificativ\u0103 a ratei de r\u0103spuns, durata controlului bolii \u0219i supravie\u021buirea global\u0103 pentru pacien\u021bii cu melanom metastatic pozitiv cu muta\u021bie BRAF. Terapiile moleculare \u0163intite anti BRAF (dabrafenib, vemurafenib) \u015fi anti MEK (trametinib) sunt eficace \u015fi trebuie utilizate numai la pacien\u0163ii cu muta\u0163ia BRAF V600. Asocierea dintre inhibitorii BRAF \u015fi MEK determin\u0103 ameliorarea rezultate mai bune fa\u0163\u0103 de monoterapia cu inhibitori BRAF.
\u00cen acela\u0219i timp, imunoterapia a evoluat, conduc\u00e2nd la dezvoltarea inhibitorilor \u201echeckpoint\u201d. Primul inhibitor imun checkpoint aprobat \u00een 2011 a fost ipilimumab, un anticorp IgG1 monoclonal complet umanizat, care inhib\u0103 CTLA-4. PD-1, proteina de moarte celular\u0103 programat\u0103 1, este un regulator negativ al activit\u0103\u021bii celulelor T \u0219i este exprimat\u0103 prin celule T cu expunere excesiv\u0103 la antigene. Ligandul s\u0103u, PD-L1, este exprimat frecvent \u00een celulele canceroase \u0219i \u00een limfocitele infiltratoare ale tumorii (TIL). Alt ligand, PD-L2, este exprimat \u00een principal pe celule care prezint\u0103 antigen (APC). Al\u0163i inhibitori, anticorpi anti-PD-1 – nivolumab \u0219i pembrolizumab. Au fost testate multiple vacinuri antitumorale pentru tratarea melanomului avansat. Vaccinurile vizeaz\u0103 ob\u021binerea r\u0103spunsului imun la antigene exprimate de celulele tumorale de melanom, cum ar fi antigenele asociate tumorii (TAA) sau antigenii deriva\u021bi din muta\u021bii (neoantigeni). Administrarea de ipilimumab, nivolumab, pembrolizumab, combina\u021bia dintre ipilimumab \u0219i nivolumab este considerat\u0103 actual un standard terapeutic de tratament \u00een linia I-a indiferent de status\u2013ul BRAF.
Utilizarea inhibitorilor checkpoint determin\u0103 r\u0103spunsuri durabile la mul\u021bi pacien\u021bi cu melanom metastatic, iar tratamentele actuale pot \u00eembun\u0103t\u0103\u021bi supravie\u021buirea pentru mul\u021bi pacien\u021bi cu melanom metastatic. \u00a0<\/p>\n
Sistemic treatments in advanced malignant melanoma<\/span> The prognosis of patients with metastatic cutaneous melanoma, is generally poor. Until recently, metastatic melanoma had historically been a challenging disease to treat, with a 10-year survival rate of less than 10%. Dacarbazine was the benchmark systemic therapy for this disease for more than 3 decades. after its initial approval in 1975. Scurt CV<\/span><\/p>\n Absolvent al Facult\u0103\u0163ii de Medicin\u0103 \u015fi Farmacie \u201dGrigore T. Popa\u201d Ia\u015fi, este medic primar de Oncologie Medical\u0103, \u015feful Clinicii de Oncologie Medical\u0103, Institutul Regional de Oncologie Ia\u015fi (I.R.O.) , profesor la Disciplina de Oncologie-Radioterapie, U.M.F. \u201dGrigore T. Popa\u201d Ia\u015fi. [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical”][et_pb_row custom_padding=”61px|0px|69px|0px|false|false” _builder_version=”3.18.9″][et_pb_column type=”3_5″ _builder_version=”3.18.9″][et_pb_text _builder_version=”3.19.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n Contacteaz\u0103 operatorul PDI 2019<\/p>\n [\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”3.19.4″ title_font=”||||||||”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ border_radii=”on||||” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ border_radii=”on||||” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ border_radii=”on||||” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.18.9″][et_pb_text _builder_version=”3.19.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n Operatorul PDI 2019<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”3.19.4″ text_font=”||||||||”] <\/span><\/p>\n <\/span><\/p>\n Adresa: Str. A. Panu nr. 13, Iasi<\/span> Absolvent al Facultatii de Medicina si Farmacie \u201e Grigore.T.Popa\u201d Ia\u015fi, este medic primar de Oncologie Medical\u0103, \u015feful Clinicii de Oncologie Medical\u0103, Institutul Regional de Oncologie Ia\u015fi (IRO) , profesor la Disciplina de Oncologie-Radioterapie, UMF \u201e Grigore T. Popa\u201d Ia\u015fi. Specializat la Institutul Oncologic \u201eAl Trestioreanu\u201d Bucure\u015fti \u015fi, ulterior cu stagii de preg\u0103tire \u00een Fran\u0163a, Centrul […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"class_list":["post-871","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/comments?post=871"}],"version-history":[{"count":7,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/871\/revisions"}],"predecessor-version":[{"id":4265,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/871\/revisions\/4265"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/media?parent=871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Author: Lucian Miron<\/span><\/p>\n
Recently, new classes of drugs (e.g. immune checkpoint inhibitors and small-molecule targeted drugs) have significantly improved patient prognosis, which has drastically changed the landscape of melanoma therapeutic management. The recognition of BRAF as an important tumour oncogene in melanoma has led to the development of new targeted therapies.
BRAF and MEK targeted therapy are effective and shoul be use only for patients with BRAF V600 mutated melanoma. Combination BRAF (vemurafenib, dabrafenib) and MEK (trametinib) inhibition results in improved outcomes compared to single-agent BRAF inhibition. All patients with advanced cutaneous melanoma should have their tumor evaluated for the presence of an activating BRAF mutation.
The importance of the immune system in cancer, leading to the development of checkpoint inhibitors. The development of checkpoint inhibitors as a tolerable and effective therapy for metastatic melanoma, which has demonstrated improved response rates, duration of control and overall survival for patients of patients with metastatic melanoma as these therapies are being trialled in other malignancies.
The first checkpoint inhibitors approved by the FDA in 2011 was ipilimumab, a fully human, monoclonal IgG1 antibody that inhibits CTLA-4. Approval of the two anti-PD-1 antibodies\u2014nivolumab and pembrolizumab\u2014followed. PD-1, programmed cell death protein 1, is a negative regulator of T cell activity and is expressed by T cells with excessive exposure to antigens. The other ligand, PD-L2, is expressed mainly by antigen-presenting cells (APCs). Both ligands are members of B7 protein family.
Multiple intratumoral and vaccine approaches have been tested for treating advanced melanoma. The vaccines aim to elicit immune response against antigens expressed by melanoma tumor cells, such as tumor-associated antigens (TAAs) or mutation-derived antigens (neoantigens). Administration of ipilimumab, nivolumab, pembrolizumab, the combination of ipilimumab and nivolumab, and talimogene laherparepvec (T-VEC; for patients with accessible lesions).
Immune checkpoint blockade can achieve durable responses in many patients with metastatic melanoma, and current treatments can improve survival for many metastatic melanoma patients as well as provide hope for a cure for some of them. While meaningful progress is being made, much more work still needs to be accomplished for patients with metastatic melanoma.<\/p>\n
Specializat la Institutul Oncologic \u201dAl. Trestioreanu\u201d Bucure\u015fti \u015fi, ulterior cu stagii de preg\u0103tire \u00een Fran\u0163a, Centrul \u201dLeon Berard\u201d Lyon Fran\u0163a, Perugia, Italia \u015fi alte centre. \u015ei-a sus\u0163inut teza de doctorat \u00een domeniul chimioterapiei citotoxice \u00een cancerele bronho-pulmonare non\u2013microcelulare, autor a numeroase articole \u015fi mai multe c\u0103r\u0163i de oncologie dintre care trei tratate de oncologie general\u0103 \u015fi special\u0103. Este specializat \u00een tratamentele sistemice actuale ale cancerelor: mamare, bronho-pulmonare, colo-rectale, genitale feminine, masculin, sarcoame \u015fi altele. Pred\u0103 cursuri la studen\u0163ii la medicin\u0103 U.M.F. \u201dGrigore T. Popa\u201d Ia\u015fi \u015fi este responsabil de preg\u0103tirea medicilor reziden\u0163i \u00een specialitatea de Oncologie Medical\u0103 la I.R.O. Ia\u015fi. Este investigator principal \u00een numeroase studii clinice interna\u0163ionale privind cancerele: mamare, bronho-pulmonare, heatocarcinom, colo-rectale, \u015fi cercetare a mai multe medica\u0163ii oncologice simptomatice. Participant la numeroase manifest\u0103rii oncologice regionale, na\u0163ionale \u015fi interna\u0163ionale este organizatorul \u201d\u015ecolii de Var\u0103\u201d I.R.O. (edi\u0163iile 2014, 2015, 2016, 2017 \u015fi 2018) \u015fi pre\u015fedintele manifest\u0103rii na\u0163ionale \u201dConferin\u0163ele Institutului Regional de Oncologie Ia\u015fi\u201d (CONFER) edi\u0163iile 2012-2018, membru a mai multe societ\u0103\u0163i de cancer na\u0163ionale \u015fi interna\u0163ionale precum: ESMO, ASCO, IASCL \u015fi altele.<\/p>\n<\/span><\/p>\n
\nTel.: 0332.40.88.00-05<\/span>
\nE-mail: inscrieri@pdi.ro\/2019<\/a>
\n<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"